Terns Pharmaceuticals Highlights New Preclinical Data Supporting TERN-501 in Combination with a GLP-1R Agonist for Obesity at the ADA’s 84th Annual…

TERN-501 significantly improved the efficacy of a GLP-1 receptor agonist by normalizing energy expenditure, resulting in greater weight loss, increased fat mass loss and relative preservation of lean mass TERN-501 significantly improved the efficacy of a GLP-1 receptor agonist by normalizing energy expenditure, resulting in greater weight loss, increased fat mass loss and relative preservation of lean mass

Read this article:
Terns Pharmaceuticals Highlights New Preclinical Data Supporting TERN-501 in Combination with a GLP-1R Agonist for Obesity at the ADA’s 84th Annual...

Roche launches new analytical units for cobas® pro integrated solutions delivering greater efficiency and capacity to laboratories

Basel, 24 June 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the launch of its new analytical units, cobas® c 703 and cobas® ISE neo, for the cobas® pro integrated solutions, in countries accepting the CE mark. The cobas pro integrated solutions is a scalable and modular diagnostic platform designed for high-volume laboratories. The cobas c 703 and cobas ISE neo analytical units offer cutting-edge features to help address some of the key challenges faced by diagnostic laboratories worldwide such as shortage of qualified staff and space limitations.

The rest is here:
Roche launches new analytical units for cobas® pro integrated solutions delivering greater efficiency and capacity to laboratories

AstriVax enters clinical phase with its novel vaccine platform technology

Leuven - June 24, 2024 - The first participants have been dosed in a Phase I clinical study to test the safety and efficacy of AstriVax’s prophylactic vaccines for yellow fever (AVX70120) and rabies (AVX70481) in healthy adults. The first-in-human safety and immunogenicity data generated by this study will be a stepping stone in advancing AstriVax immunotherapies to clear chronic infections such as Hepatitis B and human papillomavirus (HPV) infections.

Visit link:
AstriVax enters clinical phase with its novel vaccine platform technology

Altimmune Presents Data from Phase 2 MOMENTUM Trial of Pemvidutide in Obesity during Oral Presentation at the American Diabetes Association’s 84th…

Full analysis of body composition data showed class-leading lean mass preservation with 21.9% of weight loss attributable to lean mass and 78.1% attributable to fat Full analysis of body composition data showed class-leading lean mass preservation with 21.9% of weight loss attributable to lean mass and 78.1% attributable to fat

Follow this link:
Altimmune Presents Data from Phase 2 MOMENTUM Trial of Pemvidutide in Obesity during Oral Presentation at the American Diabetes Association’s 84th...

SPR® Therapeutics Recognized as a Top Workplace in Northeast Ohio for the Third Year in a Row

- Corporate culture remains a strength as the company experienced dynamic growth - - Corporate culture remains a strength as the company experienced dynamic growth -

More:
SPR® Therapeutics Recognized as a Top Workplace in Northeast Ohio for the Third Year in a Row

Novo Nordisk A/S: Mim8 demonstrated superior reductions in annualised bleeding rate (ABR) compared to on-demand and prior prophylaxis treatment in…

FRONTIER2 data presented at ISTH 2024 showed that up to 95% of people, who had no prior prophylaxis treatment, experienced zero treated bleeds while on Mim8

The rest is here:
Novo Nordisk A/S: Mim8 demonstrated superior reductions in annualised bleeding rate (ABR) compared to on-demand and prior prophylaxis treatment in...

OSE Immunotherapeutics Announces Commercial and Revenue Sharing Agreement in the Field of CAR T-cell Therapies

OSE Immunotherapeutics Announces Commercial and Revenue Sharing Agreement in the Field of CAR T-cell Therapies

Read the original:
OSE Immunotherapeutics Announces Commercial and Revenue Sharing Agreement in the Field of CAR T-cell Therapies

Valneva Announces Health Canada Approval of the World’s First Chikungunya Vaccine, IXCHIQ®

Saint-Herblain (France), June 24, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that Health Canada has approved IXCHIQ®, Valneva’s single-dose vaccine for the prevention of disease caused by the chikungunya virus in individuals 18 years of age and older. This decision marks the second approval the Company has received for IXCHIQ® following approval from the U.S. Food and Drug Administration (FDA) in November 2023. The European Medicines Agency (EMA) also recently recommended marketing authorization of the vaccine in Europe, and a formal decision is expected in the third quarter of 2024.

Continued here:
Valneva Announces Health Canada Approval of the World’s First Chikungunya Vaccine, IXCHIQ®

PolTREG’s type-1 diabetes Treg cell therapy PTG-007 demonstrates long-term safety and efficacy for up to 12 years

More here:
PolTREG’s type-1 diabetes Treg cell therapy PTG-007 demonstrates long-term safety and efficacy for up to 12 years

First gene therapy for prevalent pathologies in neurology receives FDA IND clearance – EG 427 initiating first-in-human clinical study

Paris, France, June 24, 2024 – EG 427, a biotechnology company leading the development of pinpoint DNA medicines for prevalent diseases in neurology based on its unique non-replicative HSV-1 vector platform, announces today that it has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for EG110A, a gene therapy for the treatment of Neurogenic Detrusor Overactivity (NDO) in Spinal Cord Injury (SCI) patients. The phase 1b/2a study is being initiated in 2 leading US institutions.

View original post here:
First gene therapy for prevalent pathologies in neurology receives FDA IND clearance - EG 427 initiating first-in-human clinical study